NCT00526058View on ClinicalTrials.gov

(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

December 31, 2008

Conditions
Hypercholesterolemia
Interventions
DEVICE

Secura then Futura

Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.

DEVICE

Futura then Secura

Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.

Trial Locations (2)

66160

University of Kansas Medical Center, Kansas City

06102

Hartford Hospital, Hartford

All Listed Sponsors
lead

B. Braun Medical Inc.

INDUSTRY

NCT00526058 - (H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol | Biotech Hunter | Biotech Hunter